We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current 0H8T market cap is 1.35B. The company's latest EPS is USD -1.2491 and P/E is -0.98.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 4.23M | 6.48M | 6.76M | 29.75M | 31.25M |
| Operating Income | -111.06M | -50.91M | -65.38M | -85.15M | -124.26M |
| Net Income | -161.35M | -51.02M | -90.87M | -86.91M | -88.48M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 98.3M | 70.78M | 251.21M | 254.6M | 197.41M |
| Total Liabilities | 28.39M | 33.13M | 53.87M | 56.98M | 40.23M |
| Total Equity | 69.91M | 37.65M | 197.34M | 197.62M | 157.18M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -96.45M | -38.63M | -52.13M | -67.57M | -78.33M |
| Investing | 105.68M | 6.39M | -167.63M | 12.63M | 46.22M |
| Financing | -30.32M | 18.37M | 225.05M | 72.87M | 26.71M |
| Market Cap | 1.35B |
| Price to Earnings Ratio | -0.98 |
| Price to Sales Ratio | 2.79 |
| Price to Cash Ratio | 2.18 |
| Price to Book Ratio | 0.55 |
| Dividend Yield | - |
| Shares Outstanding | 70.84M |
| Average Volume (1 week) | 2.19k |
| Average Volume (1 Month) | 1.98k |
| 52 Week Change | 0.00% |
| 52 Week High | 19.09 |
| 52 Week Low | 19.09 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Aclaris Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.aclaristx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
